Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Breakthrough? stool test may spot Alzheimer's before symptoms worsen

NCT ID NCT06481878

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new, non-invasive way to detect Alzheimer's disease by looking for specific proteins (amyloid and tau) in stool samples. The goal is to see if these proteins can serve as early warning signs, potentially allowing for earlier diagnosis and treatment. Researchers will compare stool samples from 115 people with and without Alzheimer's to validate this approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 115 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Single-center study, recruitment among patients consulting the CMRR of the Alpine arc

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For subjects with Alzheimer's disease MA TCM (A+ T+): * Subjects diagnosed with AD according to IWG 2021 criteria * Subject at the stage of major cognitive impairment * At least 40 years of age * Presence of a caregiver or support person * No informed opposition For subjects with AD TCm (A+ T+): * Subject diagnosed with AD according to IWG 2021 criteria * Subject at the stage of minor cognitive impairment * Minimum age 40 * No informed opposition For subjects with minor or major cognitive impairment who do not have AD TC Non-AD LCR negative (A- T-) * Subject at stage of minor or major cognitive impairment * CSF negative (A-T-) for Alzheimer's disease biomarkers: A-T- according to ATN classification * Minimum age 40 * No informed objection and TCm CSFdiscordant (A+ T-) or (A- T+): * Subject at stage of minor cognitive impairment * CSF discordant (A-T+ or A+T-) with Alzheimer's disease biomarkers * Minimum age 40 * No informed opposition For healthy volunteers (VS) : * No cognitive complaints * MMSE ≥ 26 * CDR 0 * Minimum age 40 * No informed opposition Exclusion Criteria: For MA TCM (A+ T+), MA TCm (A+T+) and TC Non MA LCR negatif (A-T-) and TCm LCRdiscordant (A+ T-) or (A- T+): * Inability to understand search instructions or to give informed non-opposition * Absence of social security affiliation or plan * Persons covered by articles L1121-5 to L1121-8 of the CSP (legally protected adult, subject under administrative or judicial supervision) For healthy volunteers: * Incapacity to understand research instructions or to give informed non-opposition * Persons covered by articles L1121-5 to L1121-8 of the CSP (legally protected adult, subject under administrative or judicial supervision) * Absence of social security affiliation or of such a scheme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grenoble Alpes University Hospital

    RECRUITING

    Grenoble, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.